Lacosamide Aurobindo

Lacosamide, the active ingredient in Lacosamide Aurobindo, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated as adjunctive therapy for focal (partial‑onset) seizures in patients who require additional seizure control. GNH USA supplies Lacosamide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication that modulates neuronal sodium channels to control seizure activity. - Adjunctive therapy for focal seizures: reduces seizure frequency when added to existing antiepileptic regimens. - Adjunctive therapy for partial‑onset seizures: improves seizure control in patients with refractory partial seizures. - Adjunctive therapy for refractory focal seizures: offers an additional option for patients not adequately controlled by other drugs.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate upset stomach. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias. - Suicidal ideation: emergence of thoughts of self‑harm. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: significant increase in liver function tests. - Hypersensitivity reactions: rash, swelling, or anaphylaxis. - Respiratory depression: marked slowing of breathing in rare cases.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: monitor renal function and adjust dosing if necessary. - Hepatic impairment: use with caution and observe liver enzymes. - Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. - Concomitant antiepileptic drugs: assess for additive CNS effects. - Pregnancy: risk unknown; discuss potential benefits and risks with the patient. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may markedly lower lacosamide plasma levels. - Other sodium‑channel blockers (e.g., phenytoin): increased risk of central nervous system depression. - Drugs that prolong PR interval (e.g., quinidine): heightened risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Co‑administration with other antiepileptics (e.g., valproate): may alter seizure control and side‑effect profile. - Oral contraceptives: lacosamide may reduce contraceptive effectiveness. - Alcohol: concurrent use can increase dizziness and sedation.